SCHEDULE 13G: FGMK Entities Disclose 9.99% Stake in MAIA Biotechnology, Inc.
Beneficial Ownership Report (Schedule 13G)
FGMK Business Holdings, LLC and FGMK, LLC have jointly disclosed a 9.99% beneficial ownership stake in MAIA Biotechnology, Inc., primarily through a combination of open market purchases, private placements, and warrant exercises.
Summary
- FGMK Business Holdings, LLC and FGMK, LLC (collectively, "Reporting Persons") have filed a Schedule 13G, disclosing a combined beneficial ownership of 2,889,561 shares of MAIA Biotechnology, Inc. common stock.
- This aggregate ownership represents 9.99% of the Issuer's common stock.
- The shares held by FGMK, LLC amount to 28,448 shares, received in consideration for services rendered to MAIA Biotechnology, Inc.
- FGMK Business Holdings, LLC holds 2,861,113 shares, which includes 322,473 shares issuable upon the exercise of a warrant (FGMK Warrant) that became exercisable on September 14, 2024.
- The FGMK Warrant contains a blocker provision, preventing its exercise if it would result in beneficial ownership exceeding 9.99% of the common stock. Without this provision, the Reporting Persons would beneficially own 3,007,258 shares.
- The ownership percentage is calculated based on 25,332,069 shares outstanding as of November 12, 2024, plus additional shares from recent private placements totaling 3,279,997 shares (507,364 shares in December 2024, 1,810,000 shares in February 2025, and 952,633 shares in February 2025).
Sentiment
Score: 5
Explanation: The document is a factual regulatory filing (Schedule 13G) disclosing beneficial ownership. It is neutral in tone and does not convey positive or negative sentiment regarding the company's performance, but rather a significant investment by the reporting entities.
Positives
- The document indicates a significant, long-term investment by FGMK entities in MAIA Biotechnology, Inc., suggesting confidence in the company's prospects.
- The acquisition of shares through various means, including public offerings and participation in private placements, demonstrates a consistent and growing investment strategy by the Reporting Persons.
Negatives
- The document does not contain information that can be categorized as negative regarding the Issuer's performance or outlook.
Risks
- The FGMK Warrant includes a blocker provision that limits the holder's ability to exercise the warrant if it would result in beneficial ownership exceeding 9.99% of MAIA Biotechnology's common stock, potentially capping the Reporting Persons' direct ownership influence and future accumulation.
Future Outlook
The document, a Schedule 13G, is a beneficial ownership report and does not contain forward-looking statements or guidance regarding the Issuer's future performance or strategic direction.
Management Comments
- The document does not contain notable quotes or paraphrased statements from company management of MAIA Biotechnology, Inc. It primarily details the beneficial ownership of FGMK entities.
Industry Context
This Schedule 13G filing is a standard regulatory disclosure of a significant ownership stake by an investment entity. It does not provide information to analyze broader industry trends or competitive positioning for MAIA Biotechnology, Inc.
Comparison to Industry Standards
- This document is a beneficial ownership report and does not contain financial or operational results that can be compared to global benchmarks or specific comparable companies or projects.
Legal Proceedings
- The document does not mention any litigation or regulatory matters.
Related Party Transactions
- FGMK, LLC received 28,448 shares of Common Stock in consideration of services rendered to MAIA Biotechnology, Inc.
Stakeholder Impact
- Shareholders: The disclosure of a significant 9.99% stake by FGMK entities provides transparency regarding a major investor's position, which can influence market perception and liquidity.
- Company (MAIA Biotechnology, Inc.): The investment by FGMK entities, including participation in private placements, indicates a source of capital and potential long-term support.
Next Steps
- The document does not outline any specific future actions, events, or milestones for MAIA Biotechnology, Inc. or the Reporting Persons beyond the ongoing regulatory compliance for their ownership stake.
Key Dates
| Date | Description |
|---|---|
| 2022-08-01 | FGMK Business Holdings, LLC purchased 280,000 shares of Common Stock in a public offering. |
| 2023-04-27 | FGMK Business Holdings, LLC purchased 225,000 shares of Common Stock in a public offering. |
| 2024-03-14 | FGMK Warrant was issued. |
| 2024-09-14 | Date of event which requires filing of this statement; FGMK Warrant became exercisable; FGMK Business Holdings, LLC purchased 440,170 shares of Common Stock in a private placement. |
| 2024-11-01 | FGMK Business Holdings, LLC purchased 243,470 shares of Common Stock in a private placement. |
| 2024-11-12 | Quarterly Report on Form 10-Q filed by MAIA Biotechnology, Inc. with the SEC, reporting 25,332,069 shares of Common Stock outstanding. |
| 2024-12-10 | Current Report on Form 8-K filed by MAIA Biotechnology, Inc. with the SEC, reporting 507,364 shares of Common Stock sold in a private placement in December 2024. |
| 2025-02-19 | Current Report on Form 8-K filed by MAIA Biotechnology, Inc. with the SEC, reporting 1,810,000 shares of Common Stock sold in a private placement. |
| 2025-02-24 | Private placement of 1,810,000 shares of Common Stock closed; FGMK Business Holdings, LLC purchased 1,350,000 shares of Common Stock in a private placement. |
| 2025-02-25 | Current Report on Form 8-K filed by MAIA Biotechnology, Inc. with the SEC, reporting 952,633 shares of Common Stock sold in a private placement. |
| 2025-03-03 | Private placement of 952,633 shares of Common Stock closed; Date of filing of this Schedule 13G. |
Keywords
MAIA Biotechnology, FGMK Business Holdings, FGMK LLC, Schedule 13G, Beneficial Ownership, Common Stock, Warrant, Private Placement, SEC Filing, Investment, Shareholder, Equity Stake
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.